V

Vifor Pharma AG
SIX:VIFN

Watchlist Manager
Vifor Pharma AG
SIX:VIFN
Watchlist
Price: 166.15 CHF 0.48% Market Closed
Market Cap: 10.8B CHF
Have any thoughts about
Vifor Pharma AG?
Write Note

Relative Value

VIFN price has not been updated for more than 1 month. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of VIFN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VIFN Relative Value
Base Case
Not Available
V
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
6.2
Median 5Y
6.2
Industry
2.6
vs History
vs Industry
Median 3Y
74.7
Median 5Y
74.7
Industry
23
vs History
vs Industry
Median 3Y
20.5
Median 5Y
20.5
Industry
17.8
vs History
vs Industry
Median 3Y
38
Median 5Y
38
Industry
25.4
vs History
vs Industry
Median 3Y
3.1
Median 5Y
3.1
Industry
2.2
vs History
vs Industry
Median 3Y
5.7
Median 5Y
5.7
Industry
2.8
vs History
vs Industry
Median 3Y
9.2
Median 5Y
9.2
Industry
5.4
vs History
vs Industry
Median 3Y
14.8
Median 5Y
14.8
Industry
13.7
vs History
vs Industry
Median 3Y
28.2
Median 5Y
28.2
Industry
17.2
vs History
vs Industry
Median 3Y
18.8
Median 5Y
18.8
Industry
16.5
vs History
vs Industry
Median 3Y
32.1
Median 5Y
32.1
Industry
19.3
vs History
vs Industry
Median 3Y
2.5
Median 5Y
2.5
Industry
2

Multiples Across Competitors

VIFN Competitors Multiples
Vifor Pharma AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Vifor Pharma AG
SIX:VIFN
10.8B CHF 6.1 74.7 14.7 28.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
777.8B USD 19 92.9 49.9 55.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.2 34.9 24.3 27.7
US
Johnson & Johnson
NYSE:JNJ
367.4B USD 4.2 25 12.1 15.7
US
Merck & Co Inc
NYSE:MRK
249.6B USD 4 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
209.3B CHF 3.6 18.2 10.2 12.1
CH
Novartis AG
SIX:NOVN
180.7B CHF 4.2 12.7 10 14.9
UK
AstraZeneca PLC
LSE:AZN
154.9B GBP 4 30.7 169 253.3
IE
Endo International PLC
LSE:0Y5F
155B USD 66.9 -53 248.3 622.6
P/E Multiple
Earnings Growth
CH
V
Vifor Pharma AG
SIX:VIFN
Average P/E: 38.7
74.7
126%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
92.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
34.9
86%
US
Johnson & Johnson
NYSE:JNJ
25
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.2
32%
CH
Novartis AG
SIX:NOVN
12.7
21%
UK
AstraZeneca PLC
LSE:AZN
30.7
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -53 N/A

See Also

Discover More
Back to Top